Lightsense Technology, a Tucson-based pioneer of developing multi-spectroscopic solutions to address large problems in public health—from the opioid crisis to the pandemic, food safety and quality assurance in the pharmaceutical supply chain–has announced a new channel partnership to launch its DrugDetect-M1 device for law enforcement organizations into relevant channels in the U.S.
“We are very excited to partner with Lightsense Technology with an innovative solution for illicit drug detection for law enforcement, and, later, bringing future pathogen detection products to market,” said Robert Danese, CEO of the ICN Group. “DrugDetect-M1 serves as compelling evidence of the power of new light-based detection technology. We are happy to be a part of their efforts.”
The DrugDetect platform provides a solution that is easy to operate and offers great sensitivity with high levels of accuracy at an inexpensive price point. This platform can help with the difficult opioid epidemic by providing a new tool for law enforcement to tell quickly if a white powdery substance inside a thin plastic bag could be a threat, helping them do their job efficiently and safely.
“We are pleased to team with the ICN group to bring unique, valuable solutions to broader channels within the US,” said Terje Skotheim, founder and CEO of Lightsense Technology. “This is the beginning of a new and ongoing path to turn our advanced efforts in R&D into solutions into various channels, creating more access to our products, boosting shareholder value and providing better solutions for various problems in public health.”